Blood tests to study tumor markers in non-small cell lung cancer
Studies blood markers from tumor cells in adults with lung cancer.
Plain-language title generated from the registry record
Registry title: Analysis of Circulating Tumor Markers in Blood - ALCINA 5
Key facts
- Where
- Montpellier, FranceSee the site
Where in France
- Centre Regional de Lutte Contre le Cancer - Centre Val d'AurelleMontpellier, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Institut du Cancer de Montpellier - Val d'Aurelle
- Trial code
- NCT07060950
- Record updated
- 6 November 2026
- Original description
The circulating tumoral biomarkers in the blood are the object of numerous researches for several decades. The potential clinical interests of these circulating biomarkers are diagnostic, prognostic, predictive of the efficiency of targeted therapies (according to the mutational profile of the cancer), and could allow the study of the mechanisms of resistance under process. In the multiplicity of these blood potential biomarkers joins a permanent evolution of the technological means used to detect them/to quantify, as well as to estimate their clinical utility.Read full original descriptionShow less
Analysis of Circulating Tumor Markers in Blood - ALCINA 5
The circulating tumoral biomarkers in the blood are the object of numerous researches for several decades. The potential clinical interests of these circulating biomarkers are diagnostic, prognostic, predictive of the efficiency of targeted therapies (according to the mutational profile of the cancer), and could allow the study of the mechanisms of resistance under process. In the multiplicity of these blood potential biomarkers joins a permanent evolution of the technological means used to detect them/to quantify, as well as to estimate their clinical utility.
Inclusion: Patient presenting an invasive tumoral pathology (proved or suspected), whatever is the location or the stage,; 18 years old or higher ?; Patient who has provided informed, written, and explicit consent,; Patient affiliated with a French Social Protection System; In the case of a tumor biopsy:; Tumor considered as accessible by biopsy,; Normal hemostasis assessment (PT, APTT, platelets),; No anticoagulant or antiaggregant treatment for the biopsy.
Exclusion: Patient with a history of other invasive cancers within the 5 years preceding inclusion; Pregnant woman and/or breast-feeding,; Patient whose regular follow-up is impossible for psychological, family, social or geographical reasons,; Private persons of freedom or under guardianship,.